Abstract
Severe Acute Respiratory Syndrome (SARS) is a deadly infectious disease caused by SARS Coronavirus (SARS-CoV). Inactivated SARS-CoV has been explored as a vaccine against SARS-CoV. However, safe and potent adjuvants, especially with more efficient and economical needle-free vaccination are always needed more urgently in a pandemic. The development of a safe and effective mucosal adjuvant and vaccine for prevention of emergent infectious diseases such as SARS will be an important advancement. PIKA, a stabilized derivative of Poly (I:C), was previously reported to be safe and potent as adjuvant in mouse models. In the present study, we demonstrated that the intraperitoneal and intranasal co-administration of inactivated SARS-CoV vaccine together with this improved Poly (I:C) derivative induced strong anti-SARS-CoV mucosal and systemic humoral immune responses with neutralizing activity against pseudotyped virus. Although intraperitoneal immunization of inactivated SARS-CoV vaccine alone could induce a certain level of neutralizing activity in serum as well as in mucosal sites, co-administration of inactivated SARS-CoV vaccine with PIKA as adjuvant could induce a much higher neutralizing activity. When intranasal immunization was used, PIKA was obligatorily for inducing neutralizing activity in serum as well as in mucosal sites and was correlated with both mucosal IgA and mucosal IgG response. Overall, PIKA could be a good mucosal adjuvant candidate for inactivated SARS-CoV vaccine for use in possible future pandemic.
References
Alexopoulou L, Holt A C, Medzhitov R, et al. 2001. Recognition of double-stranded rna and activation of nf-kappab by toll-like receptor 3. Nature, 413(6857): 732–738.
Baer G M. 1981. The effect of interferon on rabies infection of animals. Tex Rep Biol Med, 41: 526–531.
Belshe R B, Mendelman P M, Treanor J, et al. 1998. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med, 338(20): 1405–1412.
Bradney C P, Sempowski G D, Liao H X, et al. 2002. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin g (igg) and iga antibodies in serum and mucosal secretions after nasal immunization. J Virol, 76(2): 517–524.
Burns J W, Siadat-Pajouh M, Krishnaney A A, et al. 1996. Protective effect of rotavirus vp6-specific iga monoclonal antibodies that lack neutralizing activity. Science, 272(5258): 104–107.
Champney K J, Levine D P, Levy H B, et al. 1979. Modified polyriboinosinic-polyribocytidylic acid complex: Sustained interferonemia and its physiological associates in humans. Infect Immun, 25(3): 831–837.
Czerkinsky C, Anjuere F, Mcghee J R, et al. 1999. Mucosal immunity and tolerance: Relevance to vaccine development. Immunol Rev, 170: 197–222.
Fouchier R A, Kuiken T, Schutten M, et al. 2003. Aetiology: Koch’s postulates fulfilled for sars virus. Nature, 423(6937): 240.
Gai W, Zou W, Lei L, et al. 2008. Effects of different immunization protocols and adjuvant on antibody responses to inactivated sars-cov vaccine. Viral Immunol, 21(1): 27–37.
Herman R, Baron S. 1971. Immunologic-mediated protection of trypanosoma congolense-infected mice by polyribonucleotides. J Protozool, 18(4): 661–666.
Ichinohe T, Watanabe I, Ito S, et al. 2005. Synthetic double-stranded rna poly(i:C) combined with mucosal vaccine protects against influenza virus infection. J Virol, 79(5): 2910–2919.
Jacobs B L, Langland J O. 1996. When two strands are better than one: The mediators and modulators of the cellular responses to double-stranded rna. Virology, 219(2): 339–349.
Kang S M, Compans R W. 2003. Enhancement of mucosal immunization with virus-like particles of simian immunodeficiency virus. J Virol, 77(6): 3615–3623.
Kapikian A Z, Hoshino Y, Chanock R M, et al. 1996. Efficacy of a quadrivalent rhesus rotavirus-based human rotavirus vaccine aimed at preventing severe rotavirus diarrhea in infants and young children. J Infect Dis, 174Suppl 1: S65–72.
Koutsky L A, Ault K A, Wheeler C M, et al. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med, 347(21): 1645–1651.
Kumar M, Carmichael G G. 1998. Antisense rna: Function and fate of duplex rna in cells of higher eukaryotes. Microbiol Mol Biol Rev, 62(4): 1415–1434.
Lamm M E. 1997. Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol, 51: 311–340.
Lau Y F, Tang L H, Ooi E E. 2009. A tlr3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine, 27(9): 1354–1364.
Lau Y F, Tang L H, Mccall A W, et al. An adjuvant for the induction of potent, protective humoral responses to an h5n1 influenza virus vaccine with antigen-sparing effect in mice. J Virol, 84(17): 8639–8649.
Lau Y L, Peiris J S. 2005. Pathogenesis of severe acute respiratory syndrome. Curr Opin Immunol, 17(4): 404–410.
Leung W K, To K F, Chan P K, et al. 2003. Enteric involvement of severe acute respiratory syndrome-associated coronavirus infection. Gastroenterology, 125(4): 1011–1017.
Levine M M. 2000. Immunization against bacterial diseases of the intestine. J Pediatr Gastroenterol Nutr, 31(4): 336–355.
Li L, Shen E-X, Huang J, et al. 2006. Pika adjuvant induces the immune responses in mouse in vitro and in vivo. Chin J Immunol, 22(11): 983–986.
Li P-P, Yang X-M, Fang Z-Z, et al. 2005. Preparation of inactivated sars vaccine. Chin J Biologicals, 18: 390–393.
Lin H X, Gontier C, Saron M, et al. 1993. A new immunostimulatory complex (pickca) in experimental rabies: Antiviral and adjuvant effects. Arch Virol, 131(3–4): 307–319.
Lin M, Tseng H-K, Trejaut J-A, et al. 2003. Association of HLA class I with severe acute respiratory syndrome coronavirus infection. BMC Med Genet, 4: 9.
Luo J, Gai W, Lei L, et al. 2006. Prokaryotic expression of the sars-cov spike protein and preliminary studies on its mucosal immune response. J Wuhan Univ (Natural Science) 52(6): 733–738.
Mazanec M B, Kaetzel C S, Lamm M E, et al. 1992. Intracellular neutralization of virus by immunoglobulin a antibodies. Proc Natl Acad Sci USA, 89(15): 6901–6905.
Modlin J F. 2004. Poliomyelitis in the united states: The final chapter? JAMA, 292(14): 1749–1751.
Neutra M R, Kozlowski P A. 2006. Mucosal vaccines: The promise and the challenge. Nat Rev Immunol, 6(2): 148–158.
Qu X X, Hao P, Song X J, et al. 2005. Identification of two critical amino acid residues of the severe acute respiratory syndrome coronavirus spike protein for its variation in zoonotic tropism transition via a double substitution strategy. J Biol Chem, 280(33): 29588–29595.
Sambrook J F E, Maniatis T. 1989. Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press.
Shen E, Li L, Li L, et al. 2007. Pika as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with hbsag plus pika. Cell Mol Immunol, 4(2): 113–120.
Sloat B R, Cui Z. 2006. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm Res, 23(6): 1217–1226.
Subbarao K, Mcauliffe J, Vogel L, et al. 2004. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. J Virol, 78(7): 3572–3577.
Takao S I, Kiyotani K, Sakaguchi T, et al. 1997. Protection of mice from respiratory sendai virus infections by recombinant vaccinia viruses. J Virol, 71(1): 832–838.
Takasuka N, Fujii H, Takahashi Y, et al. 2004. A subcutaneously injected uv-inactivated sars coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol, 16(10): 1423–1430.
Tang J W, To K F, Lo A W, et al. 2007. Quantitative temporal-spatial distribution of severe acute respiratory syndrome-associated coronavirus (sars-cov) in postmortem tissues. J Med Virol, 79(9): 1245–1253.
Ter Meulen J, Bakker A B, Van Den Brink E N, et al. 2004. Human monoclonal antibody as prophylaxis for sars coronavirus infection in ferrets. Lancet, 363(9427): 2139–2141.
To K F, Lo A W. 2004. Exploring the pathogenesis of severe acute respiratory syndrome (sars): The tissue distribution of the coronavirus (sars-cov) and its putative receptor, angiotensin-converting enzyme 2 (ace2). J Pathol, 203(3): 740–743.
Underdown B J. 2005. Parenteral immunization induces mucosal protection: A challenge to the mucosal immunity paradigm, In: Mucosal immunology(Mestecky J, Bienenstock J, Lamm M E, et al. ed.), 3rd edition. Burlington: Elsevier Academic Press. Vol 1, p 831–840.
Verdijk R M, Mutis T, Esendam B, et al. 1999. Polyriboinosinic polyribocytidylic acid (poly(i:C)) induces stable maturation of functionally active human dendritic cells. J Immunol, 163(1): 57–61.
Xiao B G, Link H. 1997. Mucosal tolerance: A twoedged sword to prevent and treat autoimmune diseases. Clin Immunol Immunopathol, 85(2): 119–128.
Yan H, Lamm M E, Bjorling E, et al. 2002. Multiple functions of immunoglobulin a in mucosal defense against viruses: An in vitro measles virus model. J Virol, 76(21): 10972–10979.
Yang Y L, Reis L F, Pavlovic J, et al. 1995. Deficient signaling in mice devoid of double-stranded rnadependent protein kinase. Embo J, 14(24): 6095–6106.
Author information
Authors and Affiliations
Corresponding author
Additional information
Foundation items: National Natural Science Foundation of China (30670097); National Basic Research Program of China (973 Program) (2005CB522903); National Key R&D Program (2007BAI28B04); National S&T Major Project on Major Infectious Diseases (2008ZX10001-010).
Rights and permissions
About this article
Cite this article
Gai, Ww., Zhang, Y., Zhou, Dh. et al. PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV. Virol. Sin. 26, 81–94 (2011). https://doi.org/10.1007/s12250-011-3183-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12250-011-3183-z
Key words
- SARS Coronavirus (SARS-CoV)
- Immune responses
- Adjuvant
- PIKA